- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Neeraj Agarwal on PARP Inhibitor Combination Treatments for Prostate Cancer
Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.
Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses promising investigational combinations including PARP inhibitors in the treatment of prostate cancer.
Transcript
PARP inhibitors are being studied in combination with other therapies—which regimens being studied do you believe hold the most promise in prostate cancer?
I think the combination of PARP inhibitors with novel hormonal therapy definitely has promise. So whether it’s a combination of talazoparib with enzalutamide as being tested in TALAPRO-2 trial, or niraparib with abiraterone in the MAGNITUDE trial, and then olaparib with abiraterone in the PROPEL trial, I think all of these combinations have promise. Also the AMPLITUDE trial as I said early on, for patients with metastatic castration-sensitive prostate cancer, is a combination of abiraterone with niraparib that has promise, too. So I think that as a class, PARP inhibitors with novel hormonal therapy have a lot of scientific rationale. There is another clinical trial going on, the KEYLYNK trial, where olaparib is being tested in combination with pembrolizumab, which is an immune checkpoint inhibitor, in late metastatic castrate-resistant prostate cancer. I think that combination is also promising. Ultimately, the data will tell us whether these combinations are going to be approved or not, within next 1, 2, or 3 years. So we're really looking forward to the results of those trials.
Dr Jun Gong: Improved Access Closes the Gaps Between Black, White Men With Prostate Cancer
February 18th 2024Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.
Read More
Surgery, Radiation for PCa Show Equal Efficacy in Candidates for Renal Transplantation
September 27th 2023A recent study suggests that patients with high-risk prostate cancer (PCa) in need of renal transplantation should receive cancer treatment before their transplants, as surgery and radiation treatment for localized PCa appear to be equally effective in this patient population.
Read More
Racial Differences in Chemokine Expression May Contribute to Prostate Cancer Disparities
September 22nd 2023Researchers found that analyzing certain chemokine levels may help explain racial disparities in prostate cancer lethality, and that neutralizing such chemokines could potentially benefit prostate cancer treatment.
Read More
Cabozantinib Plus Atezolizumab Significantly Improves PFS in Metastatic CRPC
September 16th 2023Combination treatment with cabozantinib and atezolizumab did not produce any new safety signals in the treatment of those with metastatic castration-resistant prostate cancer in the phase 3 CONTACT-02 trial.
Read More
Expert Panel Addresses Prostate Cancer Misconceptions, Importance of Screening
September 14th 2023Panelists from the American College of Surgeons (ACS) and the American Urological Association spread awareness about the realities of prostate cancer, the importance of screening, and ways for men to approach their health concerns and prevention.
Read More
Adaptive SBRT May Reduce GU/GI Toxicity Risk in Prostate Cancer
September 8th 2023A meta-analysis found that the use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) correlated with fewer acute grade 2 or higher gastrointestinal (GI) or genitourinary (GU) toxicities compared with CT-guided non-adaptive SBRT in patients with prostate cancer.
Read More
